Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study

CONCLUSION: Median first-line PFS improved since 2014, mainly due to the introduction of pertuzumab. The outcome of patients with liver metastases appears to have improved in recent years. Patients with brain metastases had the worst PFS, which also did not improve over time.PMID:37783133 | DOI:10.1016/j.breast.2023.103583

Source: Breast - October 2, 2023 Category: Cancer & Oncology Authors: Massimo Di Maio Claudia Bighin Francesco Schettini Tommaso Ruelle Laura Marandino Alessandra Fabi Carmine De Angelis Mario Giuliano Pietro De Placido Michelino De Laurentiis Ferdinando Riccardi Caterina Picotto Fabio Puglisi Lucia Del Mastro Grazia Arpino Source Type: research